DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

17.45 0.20 (1.16%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HALO $17.45 1.16%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $17.20
Previous Close $17.25
Daily Range $16.97 - $17.58
52-Week Range $7.26 - $17.63
Market Cap $2.2B
P/E Ratio -37.50
Dividend (Yield) $0.00 (0.0%)
Volume 794,018
Average Daily Volume 1,167,208
Current FY EPS -$0.46

Sector

Healthcare

Industry

Drug Makers

Halozyme Therapeutics, Inc. (HALO) Description

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets. Website: http://www.halozyme.com/

News & Commentary

Can Pfizer’s Cholesterol Drug Catch Up To The Competition?

Pfizer’s bococizumab remains in last place in the PCSK9 race. Will it arrive too late to make a meaningful impact on the market?

New Drug Could Transform Pancreatic Cancer Treatment

Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2015 Results - Earnings Call Transcript

2 Small Biotech Stocks In Full Breakout Mode

Two Small Biotech Stocks In Full Breakout Mode

Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animal

Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals

Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog

MLV: We're Reiterating A Buy On Halozyme

Halozyme Therapeutics Spikes Up Following FDA News

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups

See More HALO News...

HALO's Top Competitors

HALO $17.45 (1.16%)
Current stock: HALO
AMGN $163.59 (-0.15%)
Current stock: AMGN
GILD $111.71 (0.44%)
Current stock: GILD
BIIB $398.68 (-0.62%)
Current stock: BIIB